A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/39 (2006.01) A61K 36/8998 (2006.01) A61P 35/00 (2006.01) A61P 37/04 (2006.01) A61K 39/395 (2006.01)
Patent
CA 2496508
The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles (WGP) as an immunomodulator by inducing a shift from a Th2 response to the Thl response, leading to an enhanced antitumor cytotoxic T-cell response.
La présente invention concerne des procédés d'utilisation de glucane soluble neutre et d'anticorps monoclonaux dans la thérapie anticancéreuse. Le bêta glucane soluble neutre (1,3; 1,6) favorise l'activité tumoricide du système immunitaire inné en se liant au récepteur protéinique de la fraction C3 du complément (CR3). Le glucane ne stimule pas l'induction des cytokines inflammatoires. L'invention se rapporte également à des procédés selon lesquels on utilise des particules de glucane entières comme immunomodulateur pour induire le passage d'une réponse Th2 à une réponse Th1, et entraîner une réponse lymphocytaire T cytotoxique antitumorale améliorée.
Gowling Lafleur Henderson Llp
University Of Louisville Research Foundation Inc.
LandOfFree
Cancer therapy using beta glucan and antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer therapy using beta glucan and antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer therapy using beta glucan and antibodies will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2086956